Avvio Medical Proudly Announces ISO 13485 Certification, Marking a Major Milestone in Global MedTech Readiness
SAN FRANCISCO, June 26, 2025--(BUSINESS WIRE)--Avvio Medical, Inc., a clinical-stage medical device company focused on transforming the treatment of kidney stone disease, is proud to announce that it has successfully achieved ISO 13485:2016 certification following its initial audit conducted by BSI (British Standards Institution). This globally recognized certification demonstrates Avvio's compliance with international standards for medical device quality management systems and reflects the company's unwavering commitment to excellence, patient safety, and operational rigor.
"This milestone is more than a regulatory requirement—it represents the fulfillment of our promise to stand up a full-scale medical device company," said Paul Molloy, CEO of Avvio Medical. "Through disciplined execution, a culture of continuous improvement, and a mindset grounded in honor, behavioral integrity, and precision, we have built a foundation for scalable, global operations." He added, "The quality culture at Avvio is not just a box-checking exercise. We embed it through storytelling, structured messaging, and principles drawn from disciplines of Lean and KAIZEN and a culture Bushidō. As we shared with the BSI audit team, our internal motto is #ImproveEverything—and this certification illustrates that we live by it."
The ISO 13485 certification now enables Avvio to fully qualify its manufacturing and design processes for commercial scaling, pursue CE marking for international distribution, and reinforce confidence among global partners, investors, and regulators. The achievement is a major step toward the company's upcoming 2026 commercial launch in the U.S. market. With this certification, Avvio affirms that it is not only compliant—but built to lead.
About the Enhanced Lithotripsy System (ELS)
The AVVIO ELS introduces microbubble enhanced acoustic cavitation lithotripsy that enables kidney stone treatments to move out of the traditional operating room and into more accessible outpatient and office-based settings. The system provides a single, minimally invasive therapy suitable for Ambulatory Surgery Centers (ASCs) and cystoscopy suites, without requiring general anesthesia, fluoroscopy, or costly capital equipment. This innovation offers compelling clinical and economic advantages for both patients and providers.
About Avvio Medical
Avvio Medical is a privately held medical technology company based in San Francisco and dedicated to transforming the treatment of urinary stones. Its breakthrough platform is designed to improve patient experience, reduce healthcare costs, and expand access to care by offering a fast, minimally invasive solution suitable for a wide range of clinical settings. The company's system eliminates the routine need for general anesthesia or X-ray imaging, streamlining the treatment pathway for both patients and healthcare professionals.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250625553966/en/
Contacts
Media Contact: Paul MolloyChief Executive OfficerAvvio Medical, Inc.Email: paul.molloy@avviomed.com Tel: (415) 887-2037
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
9 minutes ago
- Washington Post
How to protect yourself from ticks year-round
WASHINGTON — Ticks can be active in any season and it's important to check for and remove the bloodsuckers as quickly as possible — especially after you've been outside hiking, gardening or enjoying nature. 'Humans are outside more in summer so we hear about more tick infections ,' said Sam Telford, an infectious diseases expert at Tufts University. But he urges caution year-round because 'every season is tick season.'
Bloomberg
11 minutes ago
- Bloomberg
Wind, Solar Credits Face Shorter Phase-Out in GOP's New Tax Bill
Key tax incentives for US wind and solar projects would face a more aggressive phase-out in the Senate's latest version of President Donald Trump's spending package. The tweak, which follows pushback by Trump on the Inflation Reduction Act credits, would sharply limit the number of solar and wind farms that qualify for incentives, appeasing opponents while risking the ire of moderate members who argued for a slower phase-out.
Yahoo
14 minutes ago
- Yahoo
Can PayPal Stock Hit $125 in 2025?
Digital payment giant PayPal's (PYPL) story has been anything but smooth. After soaring in 2020 and carrying the momentum into early 2021, PYPL stock stumbled, ending three consecutive years in the red. While 2024 brought a much-needed rebound, 2025 has seen shares slip once again. Much of PayPal's decline can be traced to rising competition. Newer, faster fintech rivals have outpaced the company with sleeker, more intuitive payment solutions. Still, PayPal isn't going down without a fight. In response, PayPal brought in CEO Alex Chriss in 2023 to reset its strategy. Under his leadership, the company has launched features like one-click and express checkout while sharpening its focus on profitable growth and operational efficiency. Dear Nvidia Stock Fans, Watch This Event Today Closely A $2 Billion Reason to Sell Super Micro Computer Stock Now 3 ETFs Offering Juicy Dividend Yields of 15% or Higher Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! PayPal's ever-expanding partner network — featuring giants such as Amazon (AMZN), Shopify (SHOP), Apple (AAPL), Alphabet (GOOGL), and Meta Platforms (META) — also remains a powerful asset. With Wall Street's highest target pegged at $125 for the stock, can PayPal rally hard enough to hit that mark before the year wraps? PayPal runs a global technology platform that connects merchants and consumers through a dynamic two-sided network. Whether shopping online or in-person, users can pay, get paid, transfer, or withdraw funds using a wide range of options, including bank accounts and cards, PayPal and Venmo balances, cryptocurrency, and more — making digital payments seamless and accessible worldwide. With its market capitalization currently hovering around $71 billion, PayPal remains a major player in the fintech space. However, its stock performance tells a different story. Delivering a 25% return over the past one year, the stock has taken a 14% hit so far in 2025, underperforming the broader S&P 500 Index ($SPX) by a wide margin, with the benchmark up 4.4% year-to-date (YTD). PYPL stock touched a YTD high of $93.25 in January but has since fallen more than 21% from that peak. Considering its sluggish price action, PayPal now appears to be a potential value play. The stock is trading at just 14 times forward earnings and 2.25 times sales, which is significantly below its five-year averages. For investors hunting for discounted fintech names, PayPal's current valuation could offer an attractive entry point. PayPal delivered its fiscal 2025 first-quarter earnings on April 29. The results were a mixed bag, showing a slight revenue miss but a strong profit beat. Sales rose just 1% year-over-year (YOY) to $7.8 billion, falling short of expectations. However, the company made it clear this was by design. PayPal emphasized its strategic pivot toward profitability, deliberately phasing out lower-margin revenue streams. That shift paid off on the bottom line. Adjusted EPS came in at $1.33, up 23% from a year ago and beating Wall Street estimates by an impressive 15.7% margin. PayPal continued to strengthen its financial footing in Q1, with transaction margin dollars — the company's core profitability metric — rising 7% to $3.7 billion. Active accounts grew 2% YOY to reach 436 million, reflecting steady user engagement. Backed by a strong balance sheet with $15.8 billion in cash, cash equivalents, and investments, PayPal also returned $1.5 billion to shareholders through share repurchases, underscoring its commitment to capital returns. Reflecting on the Q1 performance, Chriss noted, 'PayPal had a great start to the year and our strategy is working. This is our fifth consecutive quarter of profitable growth with progress across branded checkout, PSP, omnichannel, and Venmo.' Looking ahead, PayPal offered a dose of optimism with strong Q2 guidance, projecting adjusted EPS between $1.29 and $1.31, signaling continued momentum on the profitability front. For the full year, the company took a more cautious stance. Citing ongoing global macroeconomic uncertainty, PayPal reaffirmed its earlier guidance, expecting full-year EPS to land between $4.95 and $5.10. By comparison, analysts tracking PayPal project the company's profit to grow 9.3% annually to $5.08 per share in fiscal 2025, followed by an even stronger 11% rise to $5.64 in fiscal 2026. Overall, Wall Street sentiment toward PYPL stock remains cautiously upbeat, with analysts giving it a consensus 'Moderate Buy' rating. Of the 44 analysts offering recommendations, 16 give it a solid 'Strong Buy" rating, two suggest a 'Moderate Buy,' 22 give a 'Hold,' and the remaining four advocate for a 'Strong Sell" rating. PYPL stock's average analyst price target of $79.81 indicates 9% potential upside. But the Street-high target of $125 tells a more bullish story, implying a potential rally of 70% if the company's turnaround strategy hits its stride. On the date of publication, Anushka Mukherji did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
